Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects

Mise à jour : Il y a 4 ans
Référence : NCT02093923

Femme et Homme

Extrait

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of multiple subcutaneous administrations of DX-2930 across a range of doses in Hereditary Angioedema subjects.


Critère d'inclusion

  • hereditary angioedema

Liens